|Drug class||TYK2 inhibitor|
|Main uses||Plaque psoriasis|
|Side effects||Upper respiratory infections, herpes simplex, folliculitis, acne|
|Typical dose||6 mg OD|
|Metabolism||Liver (primarily CYP1A2)|
|Elimination half-life||10 hours|
|Chemical and physical data|
|Molar mass||422.449 g·mol−1|
|3D model (JSmol)|
Deucravacitinib, sold under the brand name Sotyktu, is a medication used to treat moderate to severe plaque psoriasis. It should not be used with other strong immunosuppressants. It is take by mouth.
Common side effects include upper respiratory infections, herpes simplex, folliculitis, and acne. Other side effects may include allergic reactions, infection, cancer, and muscle breakdown. Use in pregnancy is of unclear safety. Use is not recommended in those with significant liver problems. It is a TYK2 inhibitor.
Deucravacitinib was approved for medical use in the United States in 2022. As of 2022 it is not approved in Europe or the United Kingdom. In the United States it costs about 6,200 USD per month.
It is take at a dose of 6 mg once per day.
Mechanism of action
- "Sotyktu- deucravacitinib tablet, film coated". DailyMed. 9 September 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022.
- "Deucravacitinib". SPS - Specialist Pharmacy Service. 1 November 2018. Archived from the original on 29 June 2022. Retrieved 13 December 2022.
- Chimalakonda A, Burke J, Cheng L, Catlett I, Tagen M, Zhao Q, et al. (October 2021). "Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors". Dermatology and Therapy. 11 (5): 1763–1776. doi:10.1007/s13555-021-00596-8. PMC 8484413. PMID 34471993.
- Mullard A (September 2022). "First de novo deuterated drug poised for approval". Nature Reviews. Drug Discovery. 21 (9): 623–625. doi:10.1038/d41573-022-00139-6. PMID 35974147. S2CID 251623586.
- "U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis". Business Wire (Press release). 10 September 2022. Archived from the original on 10 September 2022. Retrieved 10 September 2022.